₹4,567.2
▲ +8.66 +0.19%
17 Jul 2026
NSE Listed
Sanofi Cons Healthc Ind Limited (SANOFICONR)
Volume: 17,994Avg Vol 1W: 5,309.4Avg Vol 1M: 10,023.252W Range:₹3,975₹5,512
Key Ratios
Checked 13h agoMarket Cap—
Current Price₹4,567.2
Previous Close₹4,558.54
High / Low (52w)₹5,512 / ₹3,975
Volume17,994
Avg Vol (1W)5,309.4
Avg Vol (1M)10,023.2
Stock P/E43.36
Book Value₹166.96
Dividend Yield—
ROE73.1%
ROA—
Revenue (TTM)₹897 Cr
Revenue Growth—
Profit Margin—
Total Debt₹0 Cr
Shares Outstanding—
Face Value₹10
EPS (TTM)₹104.39
P/B27.11
Debt / Equity0.07
50 DMA₹4,669.33
200 DMA₹4,540.94
Day change+0.19%
Price Chart
₹4,567.2▼ 10.93% · 1Y
2025-07-172026-07-16
20-day avg volume: 10K shares
Pros
- Healthy return on equity of 73.1%.
- Company is almost debt-free.
Cons
- Revenue fell 24% YoY.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹172 Cr | ₹160 Cr | ₹171 Cr | ₹173 Cr | ₹221 Cr | ₹234 Cr | ₹251 Cr | ₹229 Cr |
| EBITDA | ₹63 Cr | ₹66 Cr | ₹66 Cr | ₹67 Cr | ₹73 Cr | ₹85 Cr | ₹91 Cr | ₹91 Cr |
| Net Profit | ₹29 Cr | ₹45 Cr | ₹44 Cr | ₹50 Cr | ₹61 Cr | ₹63 Cr | ₹67 Cr | ₹68 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | ₹560 Cr | ₹738 Cr | ₹897 Cr |
| EBITDA | ₹221 Cr | ₹279 Cr | ₹316 Cr |
| Net Profit | ₹165 Cr | ₹181 Cr | ₹240 Cr |
| EPS | 71.6 | 78.59 | 104.27 |
Balance Sheet
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | ₹345 Cr | ₹431 Cr | ₹547 Cr |
| Total Liabilities | ₹138 Cr | ₹158 Cr | ₹163 Cr |
| Equity | ₹208 Cr | ₹273 Cr | ₹384 Cr |
| Total Debt | — | — | — |
Cash Flow
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating | ₹4 Cr | ₹563 Cr | ₹262 Cr |
| Investing | ₹0 Cr | ₹2 Cr | ₹8 Cr |
| Financing | ₹2 Cr | ₹-116 Cr | ₹-134 Cr |
| Free Cash Flow | ₹4 Cr | ₹563 Cr | ₹262 Cr |
Shareholding
Promoter 71.27% Institutions 20.33% Public 8.4%
Efficiency & Working Capital
ROCE75.6%
Interest Coverage161.2
Dividend Payout—
Debtor Days12 d
Inventory Days26 d
Payable Days33 d
Cash Conversion Cycle5 d
Working Capital Days38 d
Shareholding Details
As of 2026-03-31
Promoter71.3%
FII2.8%
DII17.6%
Institutions20.3%
Public8.4%
Promoter Pledge0%
No. of Shareholders48,418
Shareholding Pattern
Quarterly — figures in %. Latest 10 quarters.
| Period | Jun 2024 | Sept 2024 | Oct 2024 | Oct 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 71.3% | 71.3% | 71.3% | 71.3% |
| FIIs | 6% | 5.2% | 4.9% | 4.9% | 4.4% | 4.5% | 3.2% | 2.9% | 2.8% | 2.8% |
| DIIs | 20.9% | 24% | 24.5% | 24.5% | 25.4% | 25.5% | 16.9% | 17.2% | 17.3% | 17.6% |
| Public | 12.7% | 10.4% | 10.2% | 10.2% | 9.8% | 9.6% | 8.6% | 8.6% | 8.6% | 8.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 61,091 | 58,582 | 57,598 | 57,598 | 55,734 | 51,859 | 49,632 | 48,808 | 48,075 | 48,418 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202512 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Opella Healthcare Participations B.v. | Shareholding of Promoter and Promoter Group | 60.4% | 1.39 Cr |
| Opal Bidco Sas | Shareholding of Promoter and Promoter Group | 10.9% | 25,04,630 |
| Nippon Life India Trustee Ltd- A/c Nippon India Growth Mid Cap Fund | Public Shareholding | 4.9% | 11,16,073 |
| Aditya Birla Sun Life Trustee Private Limited A/c - Aditya Birla Sun Life Large Cap Fund | Public Shareholding | 3% | 6,96,684 |
| Sbi Dividend Yield Fund | Public Shareholding | 1.7% | 4,01,653 |
| Icici Prudential Smallcap Fund | Public Shareholding | 1.6% | 3,59,757 |
| General Insurance Corporation Of India | Public Shareholding | 1.3% | 2,99,998 |
| Hdfc Life Insurance Company Limited | Public Shareholding | 1.3% | 2,93,900 |
| Bajaj Finserv Flexi Cap Fund | Public Shareholding | 1.2% | 2,85,993 |
| Hoechst Gmbh | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanofi | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Opella Heathcare Sas, France | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Winthrop Pharma Tunisie | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Egypt Llc | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Slovakia S.r.o | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanofi Vietnam | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Opella Canada Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Gulf Fze | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Korea Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Philippines Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sa Healthcare Pty Australia | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Austria Gmbh | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Belgium Nv/sa | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Czech S.r.o. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Oh Commercial K.f.t. | Shareholding of Promoter and Promoter Group | 0% | 0 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Opella Healthcare Participations B.v. | 0 | 0% | 2026-03-31 |
| Opal Bidco Sas | 0 | 0% | 2026-03-31 |
| Hoechst Gmbh | 0 | 0% | 2026-03-31 |
| Sanofi | 0 | 0% | 2026-03-31 |
| Opella Heathcare Sas, France | 0 | 0% | 2026-03-31 |
| Winthrop Pharma Tunisie | 0 | 0% | 2026-03-31 |
| Oh Egypt Llc | 0 | 0% | 2026-03-31 |
| Oh Slovakia S.r.o | 0 | 0% | 2026-03-31 |
| Sanofi Vietnam | 0 | 0% | 2026-03-31 |
| Opella Canada Inc. | 0 | 0% | 2026-03-31 |
| Oh Gulf Fze | 0 | 0% | 2026-03-31 |
| Oh Korea Inc. | 0 | 0% | 2026-03-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Amit Jain | Chairman & Independent Directo | 2024 |
| Himanshu Bakshi | Executive Director & MD | 2024 |
| Maithilee Kaizad Mistry | Executive Director / Whole Time Director / CFO | 2024 |
| Carol-Ann Stewart | Non-Exec & Non-Independent Dir | 2024 |
| Stanislas Camart | Non-Exec & Non-Independent Dir | 2024 |
| Shobinder Duggal | Independent Non Exe. Director | 2024 |
| Suparna Pandhi | Independent Non Exe. Director | 2024 |
| Nikunjkumar Savaliya | CS / Compliance Officer / Legal Head | 2024 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Consumer Healthcare Products | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹715 Cr | 81.4% |
| Outside India | ₹164 Cr | 18.6% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 24 | 23 | 23 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2026-06-19 | ₹75.0 (750.0%) | Final |
| dividend | 2026-06-19 | ₹75 (750%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2023 | 0 | 0 | 0 | 0 | 0 | 2 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 2 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 |
Insider / Designated-Person Trades
5 recent disclosure(s)
Opal Bidco SASAcquisition · 25,04,630
Opella Healthcare Participations B.V.Acquisition · 4,865
SanofiDisposal · 4,865
Opella Healthcare Participations B.V.Acquisition · 1,39,04,722
Hoechst GmbHDisposal · 1,39,04,722
Substantial Acquisitions (SAST)
7 disclosure(s)
Open Offer11/06/2025 · 25,04,630
Inter-se Transfer25/10/2024 · 4,865
-10/10/2024 · 4,865
Inter-se Transfer10/10/2024 · 1,39,04,722
-10/10/2024 · 1,39,04,722
Inter-se Transfer10/10/2024 · 1,39,04,722
Company Information
🌐 www.sanofi.in ↗
📍 3rd Floor Sanofi House CTS, 117-B L&T Business Park Powai, Mumbai, Maharashtra, 400072
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search